These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 24461727)

  • 1. Glycemic management in ESRD and earlier stages of CKD.
    Williams ME; Garg R
    Am J Kidney Dis; 2014 Feb; 63(2 Suppl 2):S22-38. PubMed ID: 24461727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [[GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS WITH CHRONIC KIDNEY DISEASE – HOW TO CHOOSE HYPOGLYCEMIC AGENT]?].
    Baretić M; Lang VB
    Acta Med Croatica; 2016 Dec; 70(4-5):269-74. PubMed ID: 29087153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycemic control and burnt-out diabetes in ESRD.
    Kovesdy CP; Park JC; Kalantar-Zadeh K
    Semin Dial; 2010; 23(2):148-56. PubMed ID: 20374552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetes management in the kidney patient.
    Garg R; Williams ME
    Med Clin North Am; 2013 Jan; 97(1):135-56. PubMed ID: 23290735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between glycosylated hemoglobin and blood glucose during progression of chronic kidney disease.
    Agarwal R; Light RP
    Am J Nephrol; 2011; 34(1):32-41. PubMed ID: 21659737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycemic Monitoring and Management in Advanced Chronic Kidney Disease.
    Galindo RJ; Beck RW; Scioscia MF; Umpierrez GE; Tuttle KR
    Endocr Rev; 2020 Oct; 41(5):756-74. PubMed ID: 32455432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers.
    Tong L; Adler S
    Postgrad Med; 2018 May; 130(4):381-393. PubMed ID: 29667921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study.
    Shurraw S; Hemmelgarn B; Lin M; Majumdar SR; Klarenbach S; Manns B; Bello A; James M; Turin TC; Tonelli M;
    Arch Intern Med; 2011 Nov; 171(21):1920-7. PubMed ID: 22123800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemoglobin A(1c) and fructosamine for assessing glycemic control in diabetic patients with CKD stages 3 and 4.
    Chen HS; Wu TE; Lin HD; Jap TS; Hsiao LC; Lee SH; Lin SH
    Am J Kidney Dis; 2010 May; 55(5):867-74. PubMed ID: 20202728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Continuous Glucose Monitoring in the Assessment and Management of Patients With Diabetes and Chronic Kidney Disease.
    Ling J; Ng JKC; Chan JCN; Chow E
    Front Endocrinol (Lausanne); 2022; 13():869899. PubMed ID: 35528010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DPP-4 Inhibitors in Diabetic Patients with Chronic Kidney Disease and End-Stage Kidney Disease on Dialysis in Clinical Practice.
    Abe M; Okada K
    Contrib Nephrol; 2015; 185():98-115. PubMed ID: 26023019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin Glargine U100 Improved Glycemic Control and Reduced Nocturnal Hypoglycemia in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3 and 4.
    Betônico CC; Titan SMO; Lira A; Pelaes TS; Correa-Giannella MLC; Nery M; Queiroz M
    Clin Ther; 2019 Oct; 41(10):2008-2020.e3. PubMed ID: 31383366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between assays of glycemia in diabetic subjects with advanced chronic kidney disease.
    Freedman BI; Shihabi ZK; Andries L; Cardona CY; Peacock TP; Byers JR; Russell GB; Stratta RJ; Bleyer AJ
    Am J Nephrol; 2010; 31(5):375-9. PubMed ID: 20299782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Glycemic Status During Progression of Chronic Kidney Disease With Early Dialysis Mortality in Patients With Diabetes.
    Rhee CM; Kovesdy CP; Ravel VA; Streja E; Brunelli SM; Soohoo M; Sumida K; Molnar MZ; Brent GA; Nguyen DV; Kalantar-Zadeh K
    Diabetes Care; 2017 Aug; 40(8):1050-1057. PubMed ID: 28592525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycated haemoglobin and the incidence of end-stage renal disease in diabetics.
    Oh SW; Kim YC; Koo HS; Jin DC; Na KY; Chae DW; Kim S; Chin HJ
    Nephrol Dial Transplant; 2011 Jul; 26(7):2238-44. PubMed ID: 21098657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice.
    Abe M; Okada K; Soma M
    Curr Drug Metab; 2011 Jan; 12(1):57-69. PubMed ID: 21303332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antidiabetic Therapy in End-Stage Renal Disease.
    Boyle SM; Simon B; Kobrin SM
    Semin Dial; 2015; 28(4):337-44. PubMed ID: 25898790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Which hypoglycaemic agents to use in type 2 diabetic subjects with CKD and how?
    Haneda M; Morikawa A
    Nephrol Dial Transplant; 2009 Feb; 24(2):338-41. PubMed ID: 19015168
    [No Abstract]   [Full Text] [Related]  

  • 19. Frequency of glycated hemoglobin monitoring was inversely associated with glycemic control of patients with Type 2 diabetes mellitus.
    Fu C; Ji L; Wang W; Luan R; Chen W; Zhan S; Xu B
    J Endocrinol Invest; 2012 Mar; 35(3):269-73. PubMed ID: 21606668
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.